BioPharma Resources

Drug Trial Radar · NCT07170189

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

A Phase 1, Open-label, Randomized, Five-Part Study to Assess the Pharmacokinetics and Safety of Tablet and Capsule Formulations of HU6 in Overweight Participants.

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Oct 13, 2025

Primary completion

Dec 4, 2025

Study completion Dec 4, 2025

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a five-part study being conducted to evaluate the safety, tolerability and pharmacokinetics of the HU6 tablet and capsule formulations at steady state in the fed and fasted state for HU6 450 mg once daily (QD) dose (as single or multiple tablets) or HU6 300 mg twice daily (BID) (supplied as two 150 mg tablets) or HU6 150 mg drug substance in a capsule × 3 (450 mg total dose) QD or HU6 150 mg granulated blend in a capsule × 3 (450 mg total dose) QD.

Conditions

  • Overweight

Interventions

  • HU6Drug

    HU6 tablet or capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. b. To estimate multiple dose plasma pharmacokinetics of HU6 with emphasis on the exposure parameter of maximum concentration (Cmax).Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.